Lv3
274 积分 2023-08-30 加入
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
1天前
待确认
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials
7天前
已完结
A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to- severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
7天前
已完结
Safety and Efficacy of the Oral IL-23 Receptor Antagonist Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
7天前
已完结
Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy
7天前
已完结
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
7天前
已完结
Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview
1个月前
已完结
General Pharmacokinetic Features of Small‐Molecule Compounds Exhibiting Target‐Mediated Drug Disposition (TMDD): A Simulation‐Based Study
1个月前
已完结
Targeting neutrophilic inflammation in obstructive airway disease - A narrative review of brensocatib therapy
1个月前
已完结
Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals
1个月前
已完结
皖公网安备34019202002308
